Agenda
Dec
2022- 04/12AAP – French Tech Health20 – Accompagnement des startups proposant des innovations de rupture sur les grands enjeux de société
- 06/12Eligo Bioscience: Powering the scale-up of its microbiome engineering platform
- 13/12CHU HEALTHTECH CONNEXION DAY
Mar
2023- 14/03Bioprocessing Summit Europe 2023
à la une
Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress
17 novembre 2022
Alderaan Biotechnology ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers.
EN SAVOIR PLUSPierre Fabre; Atara: CHMP Recommends Approval of Atara Biotherapeutics’ EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
17 novembre 2022
Atara Biotherapeutics, Inc. and Pierre Fabre today announced the CHMP of the EMA has adopted a positive opinion recommending the EC approval of EbvalloTM (tabelecleucel) as a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy.
EN SAVOIR PLUS
